Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03774914 · ClinicalTrials.gov registry record
LEMTRADA Pregnancy Registry in Multiple Sclerosis
A clinical trial, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 42
- Enrollment target
NCT03774914 is a clinical trial that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 42 participants.
The verdict
NCT03774914 has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
Primary Objective: The primary goal of this registry is to assess the risk of spontaneous abortion in prospective enrolled women exposed to LEMTRADA for multiple sclerosis. Secondary Objective: The secondary goals of this registry is to assess maternal, fetal and infant outcome in women with multiple sclerosis, exposed to LEMTRADA.
Interventions
- DRUG Alemtuzumab (GZ402673)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2021-11-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03774914
The ClinicalTrials.gov registry entry for NCT03774914 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alemtuzumab (GZ402673) is the first listed.
NCT03774914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03774914 about?
NCT03774914 is a clinical study titled "LEMTRADA Pregnancy Registry in Multiple Sclerosis". Primary Objective: The primary goal of this registry is to assess the risk of spontaneous abortion in prospective enrolled women exposed to LEMTRADA for multiple sclerosis. Secondary Objective: The secondary goals of this registry is to assess maternal, fetal and infant outcome in women with mult...
What is the current status of trial NCT03774914?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2015-09-01. Estimated completion is 2021-11-22.
What interventions are being tested in trial NCT03774914?
The interventions under investigation include: Alemtuzumab (GZ402673) (DRUG).
Who is sponsoring clinical trial NCT03774914?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.